19th Ave New York, NY 95822, USA
Join Now

Radiation Oncology Group

Portfolio Item Radiation Oncology Group
CLINICAL RESEARCH

At the Vall d’Hebron University Hospital’s Department of Radiation Oncology and VHIO, our clinicians and researchers are committed to enhancing patient care through research. Alongside our own research initiatives, we actively engage in numerous national and international projects. As active members of internationally recognized research organizations, such as the European Organisation for Research and Treatment of Cancer (EORTC), the International Society of Paediatric Oncology (SIOP), the GETUG radiation oncology group, and the Radiogenomics consortium, we collaborate to drive advancements in the field.

We mainly focus on clinical research, but also support translational research projects led by different VHIO groups. In 2023, we (co) authored 26 articles, and have collaborated in more than 40 clinical trials.

Our department is equipped with 4 accelerators and 1 dual energy computed tomography (CT) scanner, and incorporates cutting-edge technologies. The implementation of these incredibly complex techniques requires additional expertise provided by our department, in addition to specialized trainings for indications, operating procedures, quality control, and the incorporation of novel tools and approaches for data analysis.

We treat over 80% of pediatric patients in Catalonia requiring radiotherapy. We also manage very complex cases from other autonomous regions in Spain that do not have the necessary technology in-house. We also offer treatment to patients coming to us from abroad.

Technology:

In tertiary care, we provide complex irradiation techniques including volumetric modulated arc therapy (VMAT), image-guided radiation therapy (IGRT), stereotactic ablative radiotherapy (SABR), radiosurgery or re-irradiation. In this regard, we are participating in clinical trials to evaluate dose escalation in head and neck tumors, fiducial markers in both prostate and breast cancer IGRT, and stereotactic body radiotherapy (SBRT) in breast cancer. We are also assessing response to toxicity based on genomic polymorphisms. We have also established our department as a reference in radiosurgery and sarcoma.

Techniques:

• SABR. This complex technique consists of delivering high dose radiation to localized tumors in three or five fractions. While this treatment approach achieves a high tumor control rate with fewer secondary side effects, quality parameters are essential since even small variations can lead to high toxicity or poor tumor control. We use this technique in lung, pancreatic, and adrenal tumors, as well as liver, lymph node, and bone metastases.

• Breathing control for the treatment of tumors that are located in moving body regions such as the lungs and liver. Therapy is synchronized with respiratory rhythm. This technique is especially indicated in SBRT.

• Deep inspiration breath hold (DIBH). Deep breathing ensures that the heart moves away from the chest. This reduces the dose received by the heart.

• For prostate cancer treatment with hypofractionated therapy, we apply real-time tumor-tracking radiotherapy (RTRT). This technique involves placing markers on the prostate, which the system identifies and tracks during treatment.

• We utilize Adaptive Radiotherapy (ART) for treating gynecological and bladder tumors, as they can shift and change position during treatment.

• Radiosurgery for the treatment of small brain tumors and/or metastases.

• We employ Stereotactic Radiotherapy (SRT) to treat refractory ventricular arrhythmias. For treatment planning, a 4-dimensional CT scan is used to monitor respiratory and cardiac movements, while the defibrillator maintains a constant heart rate of 100 beats per minute. Through using an ADAS 3D image processing tool, we are able to integrate available images with Electroanatomic Mapping (EAM) and radiotherapy planning to deliver optimal personalized treatment to patients.

• Holocranial irradiation with hippocampal protection allows us to reduce long-term toxicity associated to treatment.

Figure: Volumetric modulated arc therapy (VMAT) dose distribution for total body irradiation (TBI).
Xavier Maldonado
Group Leader
Biosketch

Research Lines

  • Technology development: acquiring new equipment to implement cutting-edge radiation oncology techniques, including rotational radiotherapy with volumetric modulated arc therapy (VMAT), respiratory control radiotherapy (RT4D), and image-guided radiotherapy (IGRT), in the clinic.
  • Translational research: translate new mechanistic insights into personalized radiation therapy and biomarker-driven strategies tailored to each patient’s clinical and molecular features.
  • Quality & safety: renewal of the ISO 9001/2015 and UNE 17009:2013 certified accreditation program for radiation oncology, and the accreditation by the Organisation of European Cancer Institutes (OECI) for our oncohematology program at the Vall d’Hebron University Hospital.
  • Clinical research: advance clinical research in radiogenomics, nanoparticles, polymorphisms and radioimmunotherapy (RIT).

Team

Group Leader
Xavier Maldonado
Radiation Oncologists
Manel Altabas
Sergio Benavente
André Geng
Alexandra Giraldo
Raquel Granado
Soraya Mico
Begoña Navalpotro
Monica Ramos
Victoria Reyes
Ramona Verges

Publications

Most relevant scientific publications

  • Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P, But-Hadzic J, Widder J, Geets X, Bral S, Lambrecht M, Billiet C, Sirak I, Ramella S, Giovanni Battista I, Benavente S, Zapatero A, Romero F, Zilli T, Khanfir K, Hemmatazad H, de Bari B, Klass DN, Adnan S, Peulen H, Salinas Ramos J, Strijbos M, Popat S, Ost P, Guckenberger M. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023 Mar;24(3):e121-e132.
  • Ma TM, Sun Y, Malone S, Roach M 3rd, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, Spratt DE, Kishan AU; Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2023 Feb 1;41(4):881-892.
  • Jandu HK, Veal CD, Fachal L, Luccarini C, Aguado-Barrera ME, Altabas M, Azria D, Baten A, Bourgier C, Bultijnck R, Colciago RR, Farcy-Jacquet MP, Chang-Claude J, Choudhury A, Dunning A, Elliott RM, Green S, Gutiérrez-Enríquez S, Herskind C, Lambrecht M, Monten C, Rancati T, Reyes V, Rosenstein BS, De Ruysscher D, Carmen De Santis M, Seibold P, Sperk E, Veldwijk M, Paul Symonds R, Stobart H, Taboada-Valladares B, Vega A, Veldeman L, Webb AJ, Weltens C, West CM, Rattay T, Talbot CJ; REQUITE consortium. Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer. Radiother Oncol. 2023 Oct;187:109806.
  • Giraldo A, Geng AAA, Ramos M, Recalde E, Garre J, Maldonado X, Giralt J. et al. Evaluation of Pulmonary Functions by Spirometry after Stereotactic Body Radiotherapy in Lung Tumors. Medical Research Archives, [S.l.], v. 11, n. 6, june 2023. ISSN 2375-1924.
  • Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar 1;8(3):e216871.
  • Zapatero A, Guerrero A, Maldonado X, Álvarez A, San-Segundo CG, Rodríguez MÁC, Solé JM, Olivé AP, Casas F, Boladeras A, de Vidales CM, de la Torre MLV, Vara S, Sanz JL, Calvo FA. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol. 2022 May;23(5):671-681.
  • Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE; MARCAP Consortium group. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 Feb;23(2):304-316.
  • Biau J, Nutting C, Langendijk JA, Frédéric-Moreau T, Thariat J, Piram L, Bellini R, Saroul N, Pham Dang N, O’Sullivan B, Giralt J, Blanchard P, Bourhis J, Lapeyre M. Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers. Radiother Oncol. 2022 May;170:48-54.
  • Vázquez M, Altabas M, Moreno DC, Geng AA, Pérez-Hoyos S, Giralt J. 30-Day Mortality Following Palliative Radiotherapy. Front Oncol. 2021 Apr 23;11:668481.
  • Huijskens SC, Kroon PS, Gaze MN, Gandola L, Bolle S, Supiot S, Abakay CD, Alexopoulou A, Bokun J, Chojnacka M, Escande A, Giralt J, Harrabi S, Maduro JH, Mandeville H, Mussano A, Napieralska A, Padovani L, Scarzello G, Timmermann B, Claude L, Seravalli E, Janssens GO. Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey. Eur J Cancer. 2021 Mar;145:121-131.
  • Zapatero A, Álvarez A, Guerrero A, Maldonado X, González San Segundo C, Cabeza MA, Martín de Vidales C, Solé JM, Pedro Olivé A, Casas F, Boladeras A, Vázquez de la Torre ML, Vara S, Calvo FA. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiother Oncol. 2021 Jul;160:115-119.
  • Warren GW, Lim VS, Chowdhary M, Marwaha G, Abd Elbadee OM, Kirakli EK, Billiet C, Marin AG, Ramos M, Suppli MH, McGinnis GJ, Adjei AA. New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019. J Thorac Oncol. 2021 Nov;16(11):1946-1951.
  • Thomson DJ, Palma D, Guckenberger M, Balermpas P, Beitler JJ, Blanchard P, Brizel D, Budach W, Caudell J, Corry J, Corvo R, Evans M, Garden AS, Giralt J, Gregoire V, Harari PM, Harrington K, Hitchcock YJ, Johansen J, Kaanders J, Koyfman S, Langendijk JA, Le QT, Lee N, Margalit D, Mierzwa M, Porceddu S, Soong YL, Sun Y, Thariat J, Waldron J, Yom SS. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiother Oncol. 2020 Oct;151:314-321.
  • Giralt J, Tao Y, Kortmann RD, Zasadny X, Contreras-Martinez J, Ceruse P, Arias de la Vega F, Lalla RV, Ozsahin EM, Pajkos G, Mazar A, Attali P, Bossi P, Vasseur B, Sonis S, Henke M, Bensadoun RJ. Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):320-328.
  • Rattay T, Seibold P, Aguado- Barrera ME, Altabas M, Azria D, Barnett GC, Bultijnck R, Chang-Claude J, Choudhury A, Coles CE, Dunning AM, Elliott RM, Farcy Jacquet MP, Gutiérrez- Enríquez S, Johnson K, Müller A, Post G, Rancati T, Reyes V, Rosenstein BS, De Ruysscher D, de Santis MC, Sperk E, Stobart H, Symonds RP, Taboada- Valladares B, Vega A, Veldeman L, Webb AJ, West CM, Valdagni R, Talbot CJ; REQUITE consortium. External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Front Oncol. 2020 Oct 30;10:575909.
  • López-Campos F, Linares- Espinós E, Maldonado Pijoan X, Sancho Pardo G, Morgan TM, Martínez-Ballesteros C, Martínez-Salamanca J, Couñago F. Genetic testing for the clinician in prostate cancer. Expert Rev Mol 2020 Sep;20(9):933-946.
  • Verges R, Giraldo A, Seoane A, Toral E, Ruiz MC, Pons A, Giralt J. Does ITV vaginal procedure ensure dosimetric coverage during IMRT of post-operative gynaecological tumours without instructions concerning rectal filling? Rep Pract Oncol Radiother. 2018 Mar-Apr;23(2):136-142.
  • Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer. 2018 Apr;16(2):e491-e496.
  • Ajithkumar T, Horan G, Padovani L, Thorp N, Timmermann B, Alapetite C, Gandola L, Ramos M, Van Beek K, Christiaens M, Lassen-Ramshad Y, Magelssen H, Nilsson K, Saran F, Rombi B, Kortmann R, Janssens GO; SIOPE BTG Radiotherapy Group. SIOPE – Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Radiother Oncol. 2018 Aug;128(2):192-197.
  • Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, Lee A, Maingon P, Mäkitie A, Micciche’ F, Nicolai P, O’Sullivan B, Poitevin A, Porceddu S, Składowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018 Jan;126(1):3-24.
  • Rueda A, Giralt J, Mañós M, Lozano A, Sistiaga A, García-Miragall E, Cacicedo J, Esteban F, Scola B, Contreras J, Ruiz A, Carral A, Sanchez-Aniceto G, Pastor M, Herranz JJ, Bernal M, Mesía R. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2). Oral Oncol. 2017 Jul;70:65-72. doi: 10.1016/j.oraloncology.2017.04.005.
  • Mañós M, Giralt J, Rueda A, Cabrera J, Martinez-Trufero J, Marruecos J, Lopez-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F, Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesía R. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1). Oral Oncol. 2017 Jul;70:58-64. doi: 10.1016/j.oraloncology.2017.04.004.
  • Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target Oncol. 2017 Dec 14. doi: 10.1007/s11523-017-0544-z.
  • Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, Lee A, Maingon P, Mäkitie A, Micciche’ F, Nicolai P, O’Sullivan B, Poitevin A, Porceddu S, Składowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2017 Nov 24. pii: S0167-8140(17)32656-7. doi: 10.1016/j.radonc.2017.10.016.
  • Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer. 2017 Nov 30. pii: S1558-7673(17)30341-5. doi: 10.1016/j.clgc.2017.10.025.
  • Casas F, Henríquez I, Bejar A, Maldonado X, Alvarez A, González-Sansegundo C, Boladeras A, Ferrer F, Hervás A, Herruzo I, Caro M, Rodriguez I, Ferrer C. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. Clin Transl Oncol. 2017 Mar;19(3):373-378. doi: 10.1007/s12094-016-1538-5.
  • Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X, Martínez-Aguillo M, Navarro LM, Vaz-Salgado MA, Gil-Gil M. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol. 2017 Oct 30. doi:10.1007/s12094-017-1763-6.
  • Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, Auger C, Aizpurua M, Salas-Puig J, Santamarina E, Martinez-Saez E. Epileptic features and survival in glioblastomas presenting with seizures. Epilepsy Res. 2017 Feb;130:1-6.doi:10.1016/j.eplepsyres.2016.12.013.
  • Giraldo A, Benavente S, Ramos M, Vergés R, Coronil O, Arbeláez L, Maldonado X, Altabas M, Mollà M, Reyes V, Navalpotro B, Giralt J. Effectiveness of radiotherapy for metastatic spinal cord compression in patients with short life expectancy. Rep Pract Oncol Radiother. 2017 Jan-Feb;22(1):58-63.
  • Regis L, Planas J, Carles J, Maldonado X, Comas I, Ferrer R, Morote J. Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone. 2017 Jan;77(1):114-120. doi: 10.1002/pros.23256.
  • Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target Oncol. 2017 Nov 11. doi: 10.1007/s11523-017-0536-z.
  • Cambra MJ, Farrús B, Moreno F, Anglada L, Arenas M, Ballester R, Casals J, Cusidó M, García V, Gutiérrez C, Mollà M, Pedro A, Reyes V, Sanz X. Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic Calalà-Occità-Catalonia survey with 9-year follow up. Breast. 2017 Oct;35:196-202. doi: 10.1016/j.breast.2017.08.002.
  • Christiaens M, Collette S, Overgaard J, Gregoire V, Kazmierska J, Castadot P, Giralt J, Grant W, Tomsej M, Bar-Deroma R, Monti AF, Hurkmans CW, Weber DC. Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiother Oncol. 2017 Jun;123(3):424-430. doi: 10.1016/j.radonc.2017.04.019.
  • Prades J, Algara M, Espinàs JA, Farrús B, Arenas M, Reyes V, García-Reglero V, Cambra MJ, Rubio E, Anglada L, Eraso A, Pedro A, Fuentes-Raspall MJ, Tuset V, Solà J, Borras JM. Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: A mixed-methods study. Radiother Oncol. 2017 Apr;123(1):22-28. doi: 10.1016/j.radonc.2017.01.014.
  • Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017 Mar;73:38-47. doi: 10.1016/j.ejca.2016.12.007.
  • Gutiérrez Santamaría J, Masiá Gridilla J, Pamias Romero J, Giralt López-de-Sagredo J, Bescós Atín MS. Fat grafting is a feasible technique for the sequelae of head and neck cancer treatment. J Craniomaxillofac Surg. 2017 Jan;45(1):93-98. doi: 10.1016/j.jcms.2016.10.019.
  • Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, Beier F, Schulten J, Vermorken JB.p16, HPV, and Cetuximab: What Is the Evidence? Oncologist. 2017 Jul;22(7):811-822. doi: 10.1634/theoncologist.2016-0433.
  • Barrera-Ochoa S, Gallardo-Calero I, Sallent A, López-Fernández A, Vergés R, Giralt J, Aguirre-Canyadell M, Velez R. New and safe experimental model of radiation-induced neurovascular histological changes for microsurgical research. Lab Anim. 2017 Apr;51(2):124-137. doi: 10.1177/0023677216656221. Epub 2016 Jul 9.
  • Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. Eur J Cancer. 2016 Sep;64:1-11.
  • Zapatero, A, Guerrero A, Maldonado X, Alvarez A, Gonzàlez Sansegundo C, Cabeza MA, Macias V, Olivé P, Casas F, Boladeras A, Martin de Vidales C, Vázquez de la Torre M, Calvo F Late Radiation and cardiovascular adverse effects following androgen deprivation and high dose radiotherapy in prostate cáncer: Results fron DART 01/05 Randomized Phase III trial. Int J Radiation Oncol Biol Phys, 2016 Vol. 96, Issue 2, 341–348.
  • Bonner J, Giralt J, Harari P, Spencer S, Schulten J, Hossain A, Chang SC, Chin S, Baselga J. Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):842-9.
  • Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CM, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J. International Radiogenomics Consortium (RgC). Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiother Oncol. 2016 Dec;121(3):431-439.
  • Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesía R, Zhang A, Oliner KS, VanderWalde A. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):221-232.
  • Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):208-220.
  • Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodríguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villà S, Perez de la Haza A, Calvo FA. High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320-327.
  • Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J. Clin. Oncol. 2016 Apr; 34(12): 1300-8
  • Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb; 16(2): 208-20
  • Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesia R, Zhang A, Oliner KS, VanderWalde A.  Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb; 16(2): 221-32
  • Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L.  Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014 Feb; 15(2): 184-90
  • Sclafani F, González D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.  RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. Eur. J. Cancer 2014 May; 50(8): 1430-6
  • Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J.  Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 2013 Jan; 73(1): 450-8
  • Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C.  Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.BMC Cancer 2013; 13: 84
  • Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R.  Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J. Clin. Oncol. 2012 Sep; 30(26): 3187-93
  • Beltran M, Ramos M, Rovira JJ, Perez-Hoyos S, Sancho M, Puertas E, Benavente S, Ginjaume M, Giralt J.  Dose variations in tumor volumes and organs at risk during IMRT for head-and-neck cancer. J Appl Clin Med Phys 2012; 13(6): 3723

All publications

  • Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P, But-Hadzic J, Widder J, Geets X, Bral S, Lambrecht M, Billiet C, Sirak I, Ramella S, Giovanni Battista I, Benavente S, Zapatero A, Romero F, Zilli T, Khanfir K, Hemmatazad H, de Bari B, Klass DN, Adnan S, Peulen H, Salinas Ramos J, Strijbos M, Popat S, Ost P, Guckenberger M. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023 Mar;24(3):e121-e132. doi: 10.1016/S1470-2045(22)00752-5. PMID: 36858728.
  •  Hernando-Calvo A, Mirallas O, Marmolejo D, Saavedra O, Vieito M, Assaf Pastrana JD, Aguilar S, Bescós C, Lorente J, Giralt J, Benavente S, Temprana-Salvador J, Alberola M, Dienstmann R, Garralda E, Felip E, Villacampa G, Brana I. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients. Oral Oncol. 2023 Mar 27;140:106364. doi: 10.1016/j.oraloncology.2023.106364. Epub ahead of print. PMID: 36989964.
  •  Benavente S. Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer. Cancer Drug Resist. 2023 May 30;6(2):291-313. doi: 10.20517/cdr.2022.141. PMID: 37457128; PMCID: PMC10344731.
  • Rosas JC, Aguado-Barrera ME, Azria D, Briers E, Elliott R, Farcy-Jacquet MP, Giraldo A, Gutiérrez-Enríquez S, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, Sperk E, Stobart H, Talbot C, Vega A, Taboada-Valladares B, Veldeman L, Ward T, Webb A, West C, Chang-Claude J, Seibold P; REQUITE Consortium. Reply to: Comments on “(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer”. Int J Cancer. 2024 Feb 15;154(4):759-761. doi: 10.1002/ijc.34772. Epub 2023 Oct 31. PMID: 37908014.
  • Jaikuna T, Osorio EV, Azria D, Chang-Claude J, De Santis MC, Gutiérrez-Enríquez S, van Herk M, Hoskin P, Lambrecht M, Lingard Z, Seibold P, Seoane A, Sperk E, Symonds RP, Talbot CJ, Rancati T, Rattay T, Reyes V, Rosenstein BS, de Ruysscher D, Vega A, Veldeman L, Webb A, West CML, Aznar MC. Contouring variation affects estimates of normal tissue complication probability for breast fibrosis after radiotherapy. Breast. 2023 Dec;72:103578. doi: 10.1016/j.breast.2023.103578. Epub 2023 Sep 11. PMID: 37713940.
  • Rosas JC, Aguado-Barrera ME, Azria D, Briers E, Elliott R, Farcy-Jacquet MP, Giraldo A, Gutiérrez-Enríquez S, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, Sperk E, Stobart H, Talbot C, Vega A, Taboada-Valladares B, Veldeman L, Ward T, Webb A, West C, Chang-Claude J, Seibold P; REQUITE Consortium. Pre treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer. Int J Cancer. 2023 Nov 1;153(9):1579-1591. doi: 10.1002/ijc.34640. Epub 2023 Jul 5. PMID: 37403702.
  • Naderi E, Aguado-Barrera ME, Schack LMH, Dorling L, Rattay T, Fachal L, Summersgill H, Martínez-Calvo L, Welsh C, Dudding T, Odding Y, Varela-Pazos A, Jena R, Thomson DJ, Steenbakkers RJHM, Dennis J, Lobato-Busto R, Alsner J, Ness A, Nutting C, Gómez-Caamaño A, Eriksen JG, Thomas SJ, Bates AM, Webb AJ, Choudhury A, Rosenstein BS, Taboada-Valladares B, Herskind C, Azria D, Dearnaley DP, de Ruysscher D, Sperk E, Hall E, Stobart H, Chang-Claude J, De Ruyck K, Veldeman L, Altabas M, De Santis MC, Farcy-Jacquet MP, Veldwijk MR, Sydes MR, Parliament M, Usmani N, Burnet NG, Seibold P, Symonds RP, Elliott RM, Bultijnck R, Gutiérrez-Enríquez S, Mollà M, Gulliford SL, Green S, Rancati T, Reyes V, Carballo A, Peleteiro P, Sosa-Fajardo P, Parker C, Fonteyne V, Johnson K, Lambrecht M, Vanneste B, Valdagni R, Giraldo A, Ramos M, Diergaarde B, Liu G, Leal SM, Chua MLK, Pring M, Overgaard J, Cascallar-Caneda LM, Duprez F, Talbot CJ, Barnett GC, Dunning AM, Vega A, Andreassen CN, Langendijk JA, West CML, Alizadeh BZ, Kerns SL; Radiogenomics Consortium. Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad088. doi: 10.1093/jncics/pkad088.PMID: 37862240.
  •  Jandu HK, Veal CD, Fachal L, Luccarini C, Aguado-Barrera ME, Altabas M, Azria D, Baten A, Bourgier C, Bultijnck R, Colciago RR, Farcy-Jacquet MP, Chang-Claude J, Choudhury A, Dunning A, Elliott RM, Green S, Gutiérrez-Enríquez S, Herskind C, Lambrecht M, Monten C, Rancati T, Reyes V, Rosenstein BS, De Ruysscher D, Carmen De Santis M, Seibold P, Sperk E, Veldwijk M, Paul Symonds R, Stobart H, Taboada-Valladares B, Vega A, Veldeman L, Webb AJ, Weltens C, West CM, Rattay T, Talbot CJ; REQUITE consortium. Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer. Radiother Oncol. 2023 Oct;187:109806. doi: 10.1016/j.radonc.2023.109806. Epub 2023 Jul 10.PMID: 37437607.
  • Vakaet V, Deseyne P, Bultijnck R, Post G, West C, Azria D, Bourgier C, Farcy-Jacquet MP, Rosenstein B, Green S, de Ruysscher D, Sperk E, Veldwijk M, Herskind C, De Santis MC, Rancati T, Giandini T, Chang-Claude J, Seibold P, Lambrecht M, Weltens C, Janssens H, Vega A, Taboada-Valladares MB, Aguado-Barrera ME, Reyes V, Altabas M, Gutiérrez-Enríquez S, Monten C, Van Hulle H, Veldeman L Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data: dosimetry, acute and two years physician and patient-reported outcomes. Acta Oncol. 2023 Sep;62(9):1036-1044. doi: 10.1080/0284186X.2023.2240486. Epub 2023 Aug 7.PMID: 37548182.
  • AJ, Harper E, Rattay T, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Cicchetti A, De Ruysscher D, De Santis MC, Dunning AM, Elliott RM, Fachal L, Gómez-Caamaño A, Gutiérrez-Enríquez S, Johnson K, Lobato-Busto R, Kerns SL, Post G, Rancati T, Reyes V, Rosenstein BS, Seibold P, Seoane A, Sosa-Fajardo P, Sperk E, Taboada-Valladares B, Valdagni R, Vega A, Veldeman L, Ward T, West CM, Symonds RP, Talbot CJ; REQUITE Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort.Webb Consortium. EBioMedicine. 2022 Oct;84:104269. doi: 10.1016/j.ebiom.2022.104269. Epub 2022 Sep 18.PMID: 36130474.
  • Eraso A, Sanz J, Mollà M, Reyes V, Pedro A, Arenas M, Martinez E, Ballester R, Cambra MJ, García V, Prades JL, Borras JM, Algara M. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group.Clin Transl Oncol. 2022 Aug;24(8):1580-1587. doi: 10.1007/s12094-022-02798-8. Epub 2022 Feb 21. PMID: 35190961.
  • Aldraimli M, Osman S, Grishchuck D, Ingram S, Lyon R, Mistry A, Oliveira J, Samuel R, Shelley LEA, Soria D, Dwek MV, Aguado-Barrera ME, Azria D, Chang-Claude J, Dunning A, Giraldo A, Green S, Gutiérrez-Enríquez S, Herskind C, van Hulle H, Lambrecht M, Lozza L, Rancati T, Reyes V, Rosenstein BS, de Ruysscher D, de Santis MC, Seibold P, Sperk E, Symonds RP, Stobart H, Taboada-Valadares B, Talbot CJ, Vakaet VJL, Vega A, Veldeman L, Veldwijk MR, Webb A, Weltens C, West CM, Chaussalet TJ, Rattay T; REQUITE consortiumDevelopment and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. Adv Radiat Oncol. 2022 Jan 3;7(3):100890. doi: 10.1016/j.adro.2021.100890. eCollection 2022 May-Jun. PMID: 35647396.
  • Giraldo A, Geng AAA, Ramos M, Recalde E, Garre J, Maldonado X, Giralt J.  et al. Evaluation of Pulmonary Functions by Spirometry after Stereotactic Body Radiotherapy in Lung Tumors. Medical Research Archives, [S.l.], v. 11, n. 6, june 2023. ISSN 2375-1924.
  • Rosas JC, Aguado-Barrera ME, Azria D, Erik Briers, Rebecca Elliott, Marie-Pierre Farcy-Jacquet, Alexandra Giraldo, et al. (Pre) treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer. Int J Cancer. 2023;1‐13. doi:10.1002/ijc.34640.
  • Soumyajit Roy, Tahmineh Romero,Jeff M. Michalski, Felix Y. Feng, Jason Efstathiou, Colleen A.F. Lawton,Michel Bolla, Philippe Maingon,Theo de Reijke,David Joseph, Wee Loon Ong, Matthew R. SydesDavid P. Dearnaley, Alison C. Treep ; Nathalie Carrierp Abdenour Nabid, p Luis Souhami,Luca Incrocci,Wilma D. Heemsbergen, p Floris J. Pos,pAlmudena Zapatero,Araceli Guerrero, Ana Alvarez,Carmen Gonzalez San-Segundo, Xavier Maldonado, Robert E. Reiter,Matthew B. Rettig,Nicholas G. Nickols, Michael L. Steinberg, Luca F. Valle, T. Martin Ma, Matthew J. Farrell, Beth K. Neilsen, Jesus E. Juarez, Jie Deng, Sitaram Vangala, Norbert Avril, Angela Y. Jia, Nicholas G. Zaorsky, Yilun Sun, Daniel Spratt and Amar U. Kishan, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. J Clin Oncol. 2023, jul. 12. doi:10.1200/JCO.23.00617.
  • Gómez-Aparicio MA, López-Campos F, Lozano AJ, Maldonado X, Caballero B, Zafra J, Suarez V, Moreno E, Arcangeli S, Scorsetti M, Couñago F. Novel Approaches in the Systemic Management of High-Risk Prostate Cancer. Clin Genitourin Cancer. 2023 Dec;21(6):e485-e494. doi: 10.1016/j.clgc.2023.06.001.
  • Bonet M, González D, Baquedano JE, García E, Altabas M, Casas F, Feltes N,Ferrer F, Foro P, Fuentes R, Galdeano M, Gomez D, Henriquez I, Jové J, Lozano J,Maldonado X, Mases J, Membrive I, Paredes S, Roselló À, Sancho G, Mira M. Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus. Clin Transl Oncol. 2022 Nov 27. doi: 10.1007/s12094-022-03005-4. Epub ahead of print. PMID: 36436177.
  • Ting Martin Ma, MD, Yilun Sun,Shawn Malone, Mack Roach III, David Dearnaley,; Thomas M. Pisansky, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou, Isabel Syndikus, Emma C. Hall , Alison C. Tree, Matthew R. Sydes, Claire Cruickshank, Soumyajit Roy, Michel Bolla, Philippe Maingon, Theo De Reijke, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Tahmineh Romero, Michael L. Steinberg, Luca F. Valle,; Matthew B. Rettig, Nicholas G. Nickols, Jonathan E. Shoag, Robert E. Reiter, Nicholas G. Zaorsky, Angela Y. Jia, Jorge A. Garcia, Daniel E. Spratt, and Amar U. Kishan, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigator. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized. J Clin Oncol. 2023 Feb 1;41(4):881-892. doi: 10.1200/JCO.22.00970.
  • Sánchez-Artuñedo D, Reyes López V, Granado Carrasco R, Beltran-Vilagrasa M, Duch-Guillen MA, Hermida-López M.Gamma passing rates of daily EPID transit images correlate to PTV coverage for breast cancer IMRT treatment plans. J Appl Clin Med Phys. 2023;24:e13913.
  • Ma TM, Sun Y, Malone S, Roach M 3rd, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, Spratt DE, Kishan AU; Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2023 Feb 1;41(4):881-892. doi: 10.1200/JCO.22.00970. Epub 2022 Oct 21. PMID: 36269935; PMCID: PMC9902004.
  • Lara PC, Rodríguez-Melcón JI, Palacios-Eito A, Lozano A, Hervás-Morón A, Villafranca E, Gómez-Iturriaga A, Sancho G, Maldonado X. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. Front Oncol. 2022 Jul 14;12:891886. doi: 10.3389/fonc.2022.891886. PMID: 35912190; PMCID: PMC9329530.
  • Gómez-Aparicio MA, López-Campos F, Pelari-Mici L, Buchser D, Pastor J, Maldonado X, Zafra J, Tree AC, Bultijnck R, Sargos P, Ost P, Couñago F. Bone health and therapeutic agents in advanced prostate cancer. Front Biosci (Landmark Ed). 2022 Jan 18;27(1):34. doi: 10.31083/j.fbl2701034. PMID: 35090339.
  • Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, Souhami L, Sydes MR, Dearnaley DP, Syndikus I, Tree AC, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Efstathiou JA, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Xiang M, Rettig MB, Reiter RE, Zaorsky NG, Ong WL, Dess RT, Steinberg ML, Nickols NG, Roy S, Garcia JA, Spratt DE; MARCAP Consortium. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient- data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022 Jul;82(1):106-114. doi: 10.1016/j.eururo.2022.04.003. Epub 2022 Apr 22. PMID: 35469702.
  • Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar 1;8(3):e216871. doi: 10.1001/jamaoncol.2021.6871. Epub 2022 Mar 17. PMID: 35050303; PMCID: PMC8778608.
  • Zapatero A, Guerrero A, Maldonado X, Álvarez A, San-Segundo CG, Rodríguez MÁC, Solé JM, Olivé AP, Casas F, Boladeras A, de Vidales CM, de la Torre MLV, Vara S, Sanz JL, Calvo FA. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol. 2022 May;23(5):671-681. doi: 10.1016/S1470-2045(22)00190-5. Epub 2022 Apr 12. PMID: 35427469.
  • Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE; MARCAP Consortium group. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 Feb;23(2):304-316. doi: 10.1016/S1470-2045(21)00705-
  • Fernández-Rodríguez LJ, Arens-Benites M, Maldonado X (February 24, 2022) Image-Guided Radiation Therapy for Squamous Cell Cancer of the Head and Neck in a Specialized Peruvian Public Hospital. Cureus 14(2): e22569. DOI 10.7759/cureus.22569
  • Fernández Rodríguez LJ, Maldonado X. Pineal germinoma in a young adult: a case report. Cancer Reports2022; e161, 1-8. Cancer Reports, Wiley. Doi.org/10.1002/cnr2.1611
  • Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong AM, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco BJ, Herráez AC, Gronchi A, Sy-Ortin T, Hohenberger P, de Baère T, Cesne AL, Helfre S, Saada-Bouzid E, Anghel RM, Kantor G, Montero A, Loong HH, Vergés R, Kacso G, Austen L, Servois VF, Wardelmann E, Dimitriu M, Said P, Lazar AJ, Bovée JVMG, Péchoux CL, Pápai Z. Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):422-432. doi: 10.1016/j.ijrobp.2022.07.001. Epub 2022 Jul 16.
  • Gómez-Hidalgo NR, Acosta Ú, Rodríguez TG, Mico S, Verges R, Conesa VB, Bradbury M, Pérez-Hoyos S, Pérez-Benavente A, Gil-Moreno A. Adjuvant therapy in early-stage cervical cancer after radical hysterectomy: are we overtreating our patients? A meta-analysis. Clin Transl Oncol. 2022 Aug;24(8):1605-1614. doi: 10.1007/s12094-022-02808-9. Epub 2022 Apr 19. PMID: 35441353.
  • Webb AJ, Harper E, Rattay T, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Cicchetti A, De Ruysscher D, De Santis MC, Dunning AM, Elliott RM, Fachal L, Gómez-Caamaño A, Gutiérrez-Enríquez S, Johnson K, Lobato-Busto R, Kerns SL, Post G, Rancati T, Reyes V, Rosenstein BS, Seibold P, Seoane A, Sosa-Fajardo P, Sperk E, Taboada-Valladares B, Valdagni R, Vega A, Veldeman L, Ward T, West CM, Symonds RP, Talbot CJ; REQUITE Consortium. Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort. EBioMedicine. 2022 Oct;84:104269. doi: 10.1016/j.ebiom.2022.104269. Epub 2022 Sep 18. PMID: 36130474; PMCID: PMC9486558.
  • Alba Santos-Ortega, Nuria Rivas-Gándara , Gabriel Pascual-González, Alejandro Seoane, Raquel Granado , Victoria Reyes. Multimodality imaging fusion to guide stereotactic radioablation for refractory complex ventgricular tachycardia.  HeartRhythm Case Rep 2022 Sept 16;8(12):836-839.
  • Eraso A, Sanz J, Mollà M, Reyes V, Pedro A, Arenas M, Martinez E, Ballester R, Cambra MJ, García V, Prades JL, Borras JM, Algara M. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group. Clin Transl Oncol. 2022 Aug;24(8):1580-1587. doi: 10.1007/s12094-022-02798-8. Epub 2022 Feb 21. PMID: 35190961; PMCID: PMC9283173
  • Serra-Aracil, C. Pericay, J. Badia-Closa, T. Golda, S. Biondo, P. HernándezE. Targarona, N. Borda-Arrizabalaga, A. Reina, S. Delgado, F. Vallribera, A. Caro, J. Gallego-Plazas, M. Pascual, C. Álvarez-Laso,H. G. Guadalajara-Labajo, L. Mora-Lopez. TAU-TEM collaborative group authorship Navalpotro B* Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study). Ann Oncol. Vol. 34 Issue 1p78–90 Published online: October 8, 2022.
  • Iosune Baraibar; Ariadna García; Francesc Salvà; Javier Ros; Nadia Saoudi; Raquel Comas; Gloria Castillo; Mireia Sanchís; Alejandro García-Álvarez; Jorge Hernando; Jaume Capdevila; Marta R Castells; Marc Martí; Stefania Landolfi; Eloy Espín;Begoña Navalpotro; Jorge Guevara; Cristina Dopazo; Paolo Nuciforo; Josep Tabernero; Elena Élez. Impact of the COVID-19 pandemic in the early-onset colorectal càncer. Oncol. TRANON-D-23-00191 (Accepted).
  • Garcia-Mayea Y, Benítez-Álvarez L, Sánchez-García A, Bataller M, Companioni O, Mir C,  Benavente S , Lorente J, Canela N, Fernández-Rozadilla C, Carracedo A, LLeonart ME Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma. Cancers (Basel). 2022 Nov 9;14(22):5511. doi: 10.3390/cancers14225511. PMID:36428603
  • Van der Weijst L, Aguado-Barrera ME, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, Calvo-Crespo P, Chang-Claude J, Choudhury A, Defraene G, Demontois S, Dunning AM, Elliott RM, Ennis D, Faivre-Finn C, Franceschini M, Gutiérrez-Enríquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Mollà M, Lambrecht M, Ramos M, Rancati T, Rimner A, Rosenstein BS, De Ruysscher D, Salem A, Sangalli C, Seibold P, Sosa-Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada-Lorenzo B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML; REQUITE Consortium; Lievens Y. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Lung Cancer. 2022 Apr;166:228-241. doi: 10.1016/j.lungcan.2022.03.010. Epub 2022 Mar 15. PMID: 35334417; PMCID: MC9698940.
  • van der Weijst L, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Defraene G, Demontois S, Elliott RM, Ennis D, Faivre-Finn C, Franceschini M, Giandini T, Giraldo A, Gutiérrez-Enríquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Lambrecht M, Lang P, Ramos M, Rancati T, Rimner A, Rosenstein BS, De Ruysscher D, Salem A, Sangalli C, Seibold P, Sosa Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada-Valladares B, Talbot CJ, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML, Lievens Y; REQUITE consortium. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study. Radiother Oncol. 2022 Nov;176:127-137. doi: 10.1016/j.radonc.2022.09.020. Epub 2022 Oct 3. PMID: 36195214.
  • Aldraimli M, Osman S, Grishchuck D, Ingram S, Lyon R, Mistry A, Oliveira J, Samuel R, Shelley LEA, Soria D, Dwek MV, Aguado-Barrera ME, Azria D, Chang- Claude J, Dunning A, Giraldo A, Green S, Gutiérrez-Enríquez S, Herskind C, van Hulle H, Lambrecht M, Lozza L, Rancati T, Reyes V, Rosenstein BS, de Ruysscher D, de Santis MC, Seibold P, Sperk E, Symonds P, Stobart H, Taboada-Valadares B, Talbot CJ, Vakaet VJL, Vega A, Veldeman L, eldwijk MR, Webb A, Weltens C, West CM, Chaussalet TJ, Rattay T; REQUITE consortium. Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. Adv Radiat Oncol. 2022 Jan 3;7(3):100890. doi: 10.1016/j.adro.2021.100890. PMID: 35647396; PMCID: PMC9133391.
  • Bonet M, González D, Baquedano JE, García E, Altabas M, Casas F, Feltes N, Ferrer F, Foro P, Fuentes R, Galdeano M, Gomez D, Henriquez I, Jové J, Lozano J, Maldonado X, Mases J, Membrive I, Paredes S, Roselló À, Sancho G, Mira M. Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus. Clin Transl Oncol. 2022 Nov 27. doi: 10.1007/s12094-022-03005-4. Epub ahead of print. PMID: 36436177.
  • Hoeben BAW, Pazos M, Seravalli E, Bosman ME, Losert C, Albert MH, Boterberg T, Ospovat I, Mico Milla S, Demiroz Abakay C, Engellau J, Jóhannesson V, Kos G, Supiot S, Llagostera C, Bierings M, Scarzello G, Seiersen K, Smith E, Ocanto A, Ferrer C, Bentzen SM, Kobyzeva DA, Loginova AA, Janssens GO. ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in children. Radiother Oncol. 2022 Aug;173:119-133. doi: 10.1016/j.radonc.2022.05.027. Epub 2022 May 31. PMID: 35661674.
  • Geng-Cahuayme AAA, Sáez-Giménez B, Altabas-González M, Vázquez-Varela M, Berastegui-Garcia C, Giralt-López de Sagredo J, Zapata-Ortega M, Recalde-Vizcay E, López-Meseguer M. Efficacy and safety of total lymphoid irradiation in different chronic lung allograft dysfunction phenotypes. Clin Transplant. 2023 Feb;37(2):e14891. doi: 10.1111/ctr.14891. Epub 2023 Jan 17. PMID: 36583252.
  • Hermida-López M, García-Relancio D, Comino-Muriano M, Pérez-Esteve B, Castillo-Elías E, Carrera-García Y, Giralt J. Treatment time of image-guided radiotherapy with a Halcyon 2.0 system. J Med Imaging Radiat Sci. 2022 Dec 17:S1939-8654(22)00677-4. doi: 10.1016/j.jmir.2022.12.002. Epub ahead of print. PMID: 36535858.
  • Aguado-Flor E, Fuentes-Raspall MJ, Gonzalo R, Alonso C, Ramón Y Cajal T, Fisas D, Seoane A, Sánchez-Pla Á, Giralt J, Díez O, Gutiérrez-Enríquez S. Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis. Front Oncol. 2022 May 24;12:825703. doi: 10.3389/fonc.2022.825703. PMID: 35686103; PMCID: PMC9170959.
  • Biau J, Nutting C, Langendijk JA, Frédéric-Moreau T, Thariat J, Piram L, Bellini R, Saroul N, Pham Dang N, O’Sullivan B, Giralt J, Blanchard P, Bourhis J, Lapeyre M. Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers. Radiother Oncol. 2022 May;170:48-54. doi: 10.1016/j.radonc.2022.03.005. Epub 2022 Mar 11. PMID: 35288225.
  •  Vázquez M, Altabas M, Moreno DC, Geng AA, Pérez-Hoyos S, Giralt J. 30-Day Mortality Following Palliative Radiotherapy. Front Oncol. 2021 Apr 23;11:668481.
  • Doyen J, Sunyach MP, Almairac F, Bourg V, Naghavi AO, Duhil de Bénazé G, Claren A, Padovani L, Benezery K, Noël G, Hannoun-Lévi JM, Guedea F, Giralt J, Vidal M, Baudin G, Opitz L, Claude L, Bondiau PY. Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. Front Oncol. 2021 Jan 14;10:613089.
  • Huijskens SC, Kroon PS, Gaze MN, Gandola L, Bolle S, Supiot S, Abakay CD, Alexopoulou A, Bokun J, Chojnacka M, Escande A, Giralt J, Harrabi S, Maduro JH, Mandeville H, Mussano A, Napieralska A, Padovani L, Scarzello G, Timmermann B, Claude L, Seravalli E, Janssens GO. Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey. Eur J Cancer. 2021 Mar;145:121-131.
  • Babiker H, Brana I, Mahadevan D, Owonikoko T, Calvo E, Rischin D, Moreno V, Papadopoulos KP, Crittenden M, Formenti S, Giralt J, Garrido P, Soria A, Hervás-Morón A, Mohan KK, Fury M, Lowy I, Mathias M, Feng M, Li J, Stankevich E. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Oncologist. 2021 Sep;26(9):e1508-e1513.
  • Lozano A, Marruecos J, Rubió J, Farré N, Gómez-Millán J, Morera R, Planas I, Lanzuela M, Vázquez-Masedo MG, Cascallar L, Giralt J, Escames G, Valentí V, Grima P, Bosser R, Tarragó C, Mesía R. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clin Transl Oncol. 2021 Sep;23(9):1801-1810.
  • Arrazubi V, Cajaraville G, Cantero D, Giralt J, Mesia R, Monje F, Rueda A, Sistiaga A, Suarez J, Mut A, Comellas M, Lizán L. Defining a Standard Set of Health Outcomes for Patients With Squamous Cell Carcinoma of the Head and Neck in Spain. Front Oncol. 2022 Jan 24;11:747520.
  • Zapatero A, Maldonado Pijoan X, Gómez-Caamaño A, Pardo Masferrer J, Macías Hernández V, Hervás Morón A, Muñoz García JL, Palacios Eito A, Anguita-Alonso P, González-Junco C, López Torrecilla J. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain. Health Qual Life Outcomes. 2021 Sep 25;19(1):223.
  • Díaz-Mejía N, García-Illescas D, Morales-Barrera R, Suarez C, Planas J, Maldonado X, Carles J, Mateo J. PARP inhibitors in advanced prostate cancer: when to use them? Endocr Relat Cancer. 2021 Jul 15;28(8):T79-T93.
  • Zapatero A, Álvarez A, Guerrero A, Maldonado X, González San Segundo C, Cabeza MA, Martín de Vidales C, Solé JM, Pedro Olivé A, Casas F, Boladeras A, Vázquez de la Torre ML, Vara S, Calvo FA. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiother Oncol. 2021 Jul;160:115-119.
  • López Campos F, Sancho Pardo G, Maldonado Pijoan X, Zilli T, Couñago Lorenzo F, Hervás Morón A. Is hypofractionation acceptable for prostate bed radiotherapy? Urol Oncol. 2021 Jun;39(6):346-350.
  • Warren GW, Lim VS, Chowdhary M, Marwaha G, Abd Elbadee OM, Kirakli EK, Billiet C, Marin AG, Ramos M, Suppli MH, McGinnis GJ, Adjei AA. New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019. J Thorac Oncol. 2021 Nov;16(11):1946-1951.
  • Dopazo C, Lladó L, Fondevila C, Macarulla T, Navalpotro B, Ramos E, Fabregat J, Laquente B, Navasa M, Castells L, Bilbao I, C García Valdecasas J, Charco R. Applicability and results of liver transplant combined with neoadjuvant chemo-radiotherapy in the treatment of unresectable hilar cholangiocarcinoma. Cir Esp (Engl Ed). 2021 Mar;99(3):190-199.
  • Benito V, Lubrano A, Pérez-Regadera JF, Torné A, Gil-Moreno A, Tejerizo-Garcia Á, Vergés R, Díaz-Feijoo B; SEGO Spain-GOG Group. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group. Gynecol Oncol. 2021 Aug;162(2):407-412.
  • Gallego S, Bernabeu D, Garrido-Pontnou M, Guillen G, Hindi N, Juan-Ribelles A, Márquez C, Mata C, Orcajo J, Ramírez G, Ramos M, Romagosa C, Ruano D, Rubio P, Vergés R, Valverde C; GEIS (Grupo Español de Investigación en Sarcomas), SEHOP (Sociedad Española de Hematología y Oncología Pediátrica). GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma. Clin Transl Oncol. 2021 Dec;23(12):2460-2473.
  • Samper Ots PM, Zapatero Ortuño J, Pedraza Fernández S, Mayrata Canellas E, González San Segundo C, Campo Vargas M, Caballero B, Ramos Albiac M, Vázquez Masedo G, Álvarez B, Rodríguez Villalba S, Muñoz Miguelañez T, Diezhandino Garcia P, Sancho G, Guzmán Gómez L, Tripero J, Rico Oses MR, Ibañez Villoslada C, Soler Rodríguez AMS, Chust ML, Fondevilla Soler A, Lozano Martin EM, Morillo Macias V, Fuentes Sánchez C, Torrado Moya L, Fernández López J, Solé JM, Guijarro Verdú M, Mira Flores M, Wals A, Expósito Hernández J. Impact of covid-19 on patients in radiotherapy oncology departaments in Spain. Radiother Oncol. 2021 Aug;161:148-151.
  • Giralt J, Tao Y, Kortmann RD, Zasadny X, Contreras-Martinez J, Ceruse P, Arias de la Vega F, Lalla RV, Ozsahin EM, Pajkos G, Mazar A, Attali P, Bossi P, Vasseur B, Sonis S, Henke M, Bensadoun RJ. Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2019 Oct 25. pii: S0360-3016(19)33905-7. doi: 10.1016/j.ijrobp.2019.10.023.
  • de Rojas T, Clementel E, Giralt J, Cruz O, Boterberg T, Kortmann RD, Gaze MN, Moreno L, Janssens GO; SIOP-Europe QUARTET Project and of the EORTC. Radiotherapy practice for paediatric brain tumors across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.Eur J Cancer. 2019 Jun;114:36-46. doi: 10.1016/j.ejca. 2019.03.018. Epub 2019 Apr 28.
  • Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, Kazmierska J, Langendijk JA, Ozsahin M, O’Sullivan B, Bourhis J, Grégoire V. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update.Radiother Oncol. 2019 May;134:1-9. doi: 10.1016/j.radonc.2019.01.018. Epub 2019 Jan 30.
  • Rodríguez A, Arenas M, Lara PC, López-Torrecilla J, Algara M, Conde A, Pérez-Montero H, Muñoz JL, Peleteiro P, Pérez-Calatayud MJ, Contreras J, Ferrer C; Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group. Are there enough radiation oncologists to lead the new Spanish radiotherapy?Clin Transl Oncol. 2019 Apr 3. doi: 10.1007/s12094-019-02095-x.
  • Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium.REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapyfor breast, lung or prostate cancer.Radiother Oncol. 2019 Sep;138:59-67.
  • Cambra MJ, Moreno F, Sanz X, Anglada L, Mollà M, Reyes V, Arenas M, Pedro A, Ballester R, García V, Casals J, Cusidó M, Jimenez C, Escribà JM, Macià M, Solé JM, Arcusa A, Seguí MA, Gonzalez S, Farrús B, Biete A. Role of boost radiotherapy for local control of pure ductal carcinoma in situ after breast-conserving surgery: a multicenter, retrospective study of 622 patients.Clin Transl Oncol. 2019 Jul 1.
  • Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, Gonzàlez X, Adrover E, Azaro A, Valls-Margarit M, Parra JL, Aguilar J, Vidal M, Martín A, Gavilá J, Escrivá-de-Romaní S, Perelló A, Hernando C, Lahuerta A, Zamora P, Reyes V, Alcalde M, Masanas H, Céliz P, Ruíz I, Gil M, Seguí MÀ, de la Peña L. Palbociclib and ribociclib in breastcancer: consensus workshop on the management of concomitant medication.Ther Adv Med Oncol. 2019 May 10.
  • Garcia-Mayea Y, Mir C, Muñoz L, Benavente S, Castellvi J, Temprana J, Maggio V, Lorente J, Paciucci R, LLeonart ME. Autophagy inhibition as a promising therapeutic target for laryngeal cancer. Carcinogenesis.2019 May 3. pii: bgz080. doi: 10.1093/carcin/bgz080.
  • Guillem V., Algaba F., Arranz JA., Cassinello J., Climent MA., Duran I., Gómez de Liaño A., Maldonado X., Puente J., Rubio J. NCCN Clinical Practice Gudelines in Oncology(NCCN Guidelines). European edition: Spain. Version 2.2019-August 6, 2019.
  • Font A., Luque R., Villa JC., Domenech M., Vázquez S., Gallardo E., Virizuela JA., Beato C., Morales-Barrera R., Gelabert A., Macià S., Puente J., Rubio G., Maldonado X.,Pérez Valderrama B., Pinto A., Fernández Calv o O., Grande E., Garde Noguera J., Fernández Parra E., Arranz Ja. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with treatment recommendations from the Spanish Oncology GenitoUrinary Group (SOGUG). Targeted Oncology
  • Carles, E.Gallardo, M.Doménech, A.Font, J.Bellmeunt, M.Fígols, B.Mellado, MI Sáez, C.Suárez, MJ Mémdez, P.Maroto, R.Luque, T.Portugal, R.Aldabó, T.bonfill, R.Morales-Barrera, J.García, S.Macía,X.Maldonado, P.Foro. Phase 2 Randomized Study of Radiation Therapy and 3 Year Androgen Deprivation with or without concurrent weekly Docetaxel in High-Risk localized Prostate Cancer Patients. Int J. Radiat Oncol Biol Phys. 2019 Vol. 103, Issue 2, 344–352.
  • Gil-Moreno A, Carbonell-Socias M, Salicrú S, Bradbury M, García Á, Vergés R, Puig OP, Sánchez-Iglesias JL, Cabrera-Díaz S, de la Torre J, Gómez-Hidalgo NR, Pérez-Benavente A, Díaz-Feijoo B. Nerve-sparing versus non-nerve-sparing radical hysterectomy: surgical and long-term oncological outcomes. Oncotarget. 2019 Jul 16;10(44):4598-4608,
  • Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019 Aug;20(8):1148-1159.
  • Carles J, Gallardo E, Doménech M, Font A, Bellmunt J, Figols M, Mellado B, Sáez MI, Suárez C, Méndez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, García J, Maciá S, Maldonado X, Foro P. Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients. Int J Radiat Oncol Biol Phys. 2018 Oct 12. pii: S0360-3016(18)33856-2. doi: 10.1016/j.ijrobp.2018.10.005.
  • Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A; Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR). Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. Clin Transl Oncol. 2018 Oct 6. doi: 10.1007/s12094-018-1940-2.
  • Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer. 2018 Apr;16(2):e491-e496. doi: 10.1016/j.clgc.2017.10.025.
  • Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X, Martínez-Aguillo M, Navarro LM, Vaz-Salgado MA, Gil-Gil M. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol. 2018 Jan;20(1):22-28. doi: 10.1007/s12094-017-1763-6.
  • Rodríguez A, Algara M, Monge D, López-Torrecilla J, Caballero F, Morera R, Escó R, Pérez-Montero H, Ferrer C, Lara PC; Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group. Infrastructure and equipment for radiation oncology in the Spanish National Health System: analysis of external beam radiotherapy 2015-2020. Clin Transl Oncol. 2018 Mar;20(3):402-410. doi: 10.1007/s12094-017-1727-x. Collaboradors: Ortiz MJ, Expósito J, Palacios A, Herruzo I, Medina JA, Martinez M, Bayo E, Jaén J, Peracaula FJ, Pérez C, Ramos MI, González JA, López E, Begara J, Nuño C, Bezares AB, Serradilla A, Lazo A, Tejedor M, Méndez L, Juan G, Olay L, Pardo J, Mestre F, Otón C, Fuentes C, Prada P, Pérez L, Lozano E, Villas MV, Tripero J, Lobo R, Muñoz M, Tisaire JL, Fernández J, Teijeira M, Rodríguez JR, Pérez L, López F, Ceballos A, Cantalapiedra R, Biete A, Craven J, Pedro A, Giralt J, Guedea F, Villá S, Solé JM, Eraso A, Carceller JA, Arenas M, Guix B, Miralbell R, Casals J, Muñoz J, González P, Duarte MI, Jerez JP, Mariño A, Gómez A, Muñoz V, López MD, Zugazabeitia L, Ossola G, Mañas A, Cerezo L, Ramos A, Pérez-Regadera J, Lozano MA, de Las Heras M, Pérez A, Torre A, Samper P, Ludeña B, de Dios Sáez J, Azinovic I, Rubio C, Del Cerro E, Meiriño R, García-Alejo R, Carballo N, García R, Salinas J, Fontevilla A, Martinez R, Martinez E, Alia A, Ciria JP, Rosa J, Bilbao P, Martin JC, Casquero F, Arribas L, Tormo A, Algas A, Larrea L, Soler M, Garcia E, Soler P, Santos M, Vázquez G, Cañón RM, Miró A.
  • Cabrera Rodríguez J, Cacicedo J, Giralt J, García Miragall E, Lloret M, Arias F, González Ruiz MA, Contreras J. GEORCC recommendations on target volumes in radiotherapy for Head Neck Cancer of Unkown Primary. Crit Rev Oncol Hematol. 2018 Oct;130:51-59. doi: 10.1016/j.critrevonc.2018.07.006.
  • Verges R, Giraldo A, Seoane A, Toral E, Ruiz MC, Pons A, Giralt J. Does ITV vaginal procedure ensure dosimetric coverage during IMRT of post-operative gynaecological tumours without instructions concerning rectal filling? Rep Pract Oncol Radiother. 2018 Mar-Apr;23(2):136-142. doi: 10.1016/j.rpor.2018.01.006.
  • Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio Perilongo, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; Low Grade Glioma Consortium and the participating centers. Corrigendum to “A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report” [Eur J of Canc (2017) 206-225]. Eur J Cancer. 2018 Feb;90:156-157. doi: 10.1016/j.ejca.2017.11.017. Collaboradors: Gnekow AK, Slavc I, Perilongo G, Picton S, Walker D, Stokland T, Sandstrom PE, Clausen N, Arola M, Jonsson OG, Cruz O, Navajas A, Teijeiro A, Grill J, Kalifa C, Raquin MA, Verlooy J, Hans V, Pietsch T, Scheurlen W, Hainfellner J, Giangaspero F, Ironside J, Robson K, Skullerud K, Scheie D, Nn, Ruchoux MM, Jouvet A, Figarella-Branger D, Lellouch-Toubiana A, Warmuth-Metz M, Prayer D, Calderone M, Jaspan T, Bakke SJ, Vazquez E), Couanet D, Kortmann RD, Diekmann K, Scarzello G, Taylor R, Lote K, Giralt J, Carrie C, Habrand JL, Soerensen N, Czech T, Chumas P, Gustavson B, Zerah M, Wabbels B, Pinello ML, Fielder A, Simmons I, Christoffersen T, Calaminus G, Brockmann K, Straeter R, Ebinger F, Hernaiz-Driever P, Lackner H, Kennedy C, Glaser A, Stromberg B, Indiano JM, Rodary C, Bouffet E, Frappaz D, Faldum A, Emser A, De Salvo GL, Stephens S, Machin D, Le Deley MC, Egeland T, Freemann C, Schrappe M, Sposto R.
  • Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target Oncol.2018 Feb;13(1):79. doi:10.1007/s11523-017-0544-z.
  • Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, Lee A, Maingon P, Mäkitie A, Micciche’ F, Nicolai P, O’Sullivan B, Poitevin A, Porceddu S, Składowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018 Jan;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016.
  • Lobon-Iglesias MJ, Santa-Maria Lopez V, Puerta Roldan P, Candela-Cantó S, Ramos-Albiac M, Gomez-Chiari M, Puget S, Bolle S, Goumnerova L, Kieran MW, Cruz O, Grill J, Morales La Madrid A. Tumor dissemination through surgical tracts in diffuse intrinsic pontine glioma. J Neurosurg Pediatr. 2018 Sep 7:1-6. doi: 10.3171/2018.6.PEDS17658.
  • Matamalas A, Valverde C, Benavente S, Casas-Gomila L, Romagosa C, González-Tartière P, Pellisé F. Team Approach: Metastatic Disease of the Spine. JBJS Rev. 2018 May;6(5):e6. doi: 10.2106/JBJS.RVW.17.00118.
  • Ajithkumar T, Horan G, Padovani L, Thorp N, Timmermann B, Alapetite C, Gandola L, Ramos M, Van Beek K, Christiaens M, Lassen-Ramshad Y, Magelssen H, Nilsson K, Saran F, Rombi B, Kortmann R, Janssens GO; SIOPE BTG Radiotherapy Group. SIOPE – Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Radiother Oncol. 2018 Aug;128(2):192-197. doi: 10.1016/j.radonc.2018.04.016.
  • CDK4/6 Inhibitors in Breast Cancer: Consensus Workshop on the Management of Concomitant Medication. Bellet, Meritxell; Ahmad, Faten; Valdivia, Carolina; Palomino-Doza , Julián; Gonzàlez, Xavier; Adrover, Encarna; Azaro, Analía; Vidal, Maria Martín, Anastasi; Escrivá-de-Romaní , Santiago; Perelló, Antonia; Hernando, Cristina; Lahuerta , Ainhara ;  Zamora, Pilar; Reyes, Victoria ; Alcalde, María; Masanas, Helena; Ruíz, Isabel; Gil, Miguel; Seguí, Miguel  and  de la Peña, Lorena. Therapeutic Advances in Medical Oncology. Accepted in press.
  • Rueda A, Giralt J, Mañós M, Lozano A, Sistiaga A, García-Miragall E, Cacicedo J, Esteban F, Scola B, Contreras J, Ruiz A, Carral A, Sanchez-Aniceto G, Pastor M, Herranz JJ, Bernal M, Mesía R. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2). Oral Oncol. 2017 Jul;70:65-72. doi: 10.1016/j.oraloncology.2017.04.005.
  • Mañós M, Giralt J, Rueda A, Cabrera J, Martinez-Trufero J, Marruecos J, Lopez-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F, Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesía R. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1). Oral Oncol. 2017 Jul;70:58-64. doi: 10.1016/j.oraloncology.2017.04.004.
  • Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target Oncol. 2017 Dec 14. doi: 10.1007/s11523-017-0544-z.
  • Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, Lee A, Maingon P, Mäkitie A, Micciche’ F, Nicolai P, O’Sullivan B, Poitevin A, Porceddu S, Składowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2017 Nov 24. pii: S0167-8140(17)32656-7. doi: 10.1016/j.radonc.2017.10.016.
  • Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer. 2017 Nov 30. pii: S1558-7673(17)30341-5. doi: 10.1016/j.clgc.2017.10.025.
  • Casas F, Henríquez I, Bejar A, Maldonado X, Alvarez A, González-Sansegundo C, Boladeras A, Ferrer F, Hervás A, Herruzo I, Caro M, Rodriguez I, Ferrer C. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. Clin Transl Oncol. 2017 Mar;19(3):373-378. doi: 10.1007/s12094-016-1538-5.
  • Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X, Martínez-Aguillo M, Navarro LM, Vaz-Salgado MA, Gil-Gil M. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol. 2017 Oct 30. doi:10.1007/s12094-017-1763-6.
  • M.Molla, N.Anducas, M. Simó, A.Seoane, M.Ramos, G. Cuberas, M. Beltran, J. Castell, J. Giralt. A comparative study of the target volume definition in radiotherapy with “Slow CT Scan” vs 4D PET/CT Scan in early stages non-small cell lung cancer. Rev Esp Med Nucl Imagen Mol, available online 19 Apr 2016. DOI: 10.1016/j.remn.2016.02.003.
  • Regis L, Planas J, Carles J, Maldonado X, Comas I, Ferrer R, Morote J. Free Testosterone During Androgen Deprivation Therapy Predicts Castration –Resistant Progression Better Than Total Testosterone. The Prostate, 2016, DOI 10.1002/pros.23526; 1-7
  • F. Casas, I. Henríquez. A. Bejar, X. Maldonado, A. Alvarez,C. González-Sansegundo A. Boladeras, F. Ferrer, A. Hervás, I. Herruzo, M. Caro, I. Rodriguez, C. Ferrer. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. Clin Translat Oncol 2016; 1-6, First Online: 21 October 2016 DOI: 10.1007/s12094-016-1538-5
  • Morales R, Suarez C., Martinez de Castro AM., Racca F., Valverde C., Maldonado X., Bastaros JM, Morote J., Carles J. Targeting fibroblast growth factor receptors and immune check point inhibitors of advanced bladder cancer: New direction and Hope. Cancer Treatment Reviews 50 (2016) 208-2016
  • Zapatero, A., Guerrero A., Maldonado X., Alvarez A., Gonzàlez Sansegundo C, Cabeza MA., Macias V., Olivé P., Casas F., Boladeras A., Martin de Vidales C., Vázquez de la Torre M., Calvo F. Late Radiation and cardiovascular adverse effects following androgen deprivation and high dose radiotherapy in prostate cáncer: Results fron DART 01/05 Randomized Phase III trial. Int J. Radiat oncol Biol Phys, 2016 Vol. 96, Issue 2, 341–348
  • Planas J, Celma A., Placer J., Maldonado X., Trilla E., Salvador C., LLorente D., Regis L., Cuadras M., Carles J., Morote J. Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy.” (ref. Acuro-d-16-00024r1), Actas Urol Esp, vol 40, Mayo 2016
  • Gómez Caamaño A, Zapatero A, López Torrecilla J, Maldonado X. Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain. Clin Transl Oncol Clin Transl Oncol. 2016 Sep;18(9):884-92. doi: 10.1007/s12094-015-1454-0.
  • Morote J., Maldonado X., Morales R. Cáncer de próstata. Med Clin (Barc). Vol. 146 Núm. 03 Febrero 2016. pii: S0025-7753(15)00041-X. doi: 10.1016/j.medcli.2014.12.021. [Epub ahead of print]
  • Mollà M, Saez J, Ramos M, Giraldo A, Seoane A, Andreu J, Simó M, Giralt J. Hypofractionated 3d Radiotherapy for inoperable T1-3 N0-1 non-small cell lung cancer. Br J Radiol. 2016 Mar 17:20150824. [Epub ahead of print] PMID: 26986457
  • Barrera-Ochoa S, Gallardo-Calero I, Sallent A, López-Fernández A, Vergés R, Giralt J, Aguirre-Canyadell M, Velez R. New and safe experimental model of radiation-induced neurovascular histological changes for microsurgical research. Lab Anim. 2016 Jun 29. pii: 0023677216656221. [Epub ahead of print] PMID: 27357187
  • Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. Eur J Cancer. 2016 Jun 17;64:1-11. doi: 10.1016/j.ejca.2016.05.008. [Epub ahead of print] PMID: 27323346
  • Bonner J, Giralt J, Harari P, Spencer S, Schulten J, Hossain A, Chang SC, Chin S, Baselga J. Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2016 Jul 7.
  • J. Gutiérrez , J. Masiá , J. Pamias, J. Giralt, M.S. Bescós. Fat grafting is a feasible technique for the sequelae of head and neck cancer treatment. Journal of Cranio-Maxillofacial Surgery. 2017 Jan;45(1):93-98. doi:10.1016/j.jcms.2016.10.019. Epub 2016 Nov 1.
  • Giraldo A, Benavente S, Ramos M, Vergés R, Coronil O, Arbeláez L, Maldonado X, Altabas M, Mollà M, Reyes V, Navalpotro B, Giralt J. Effectiveness of radiotherapy for metastatic spinal cord compression in patients with short life expectancy. Reports of Practical Oncology & Radiotherapy 2017, 22;1: 58-63.
  • Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Cruz J, Mulet-Margalef N, Narvaez JA, Martinez Tirado O, Valverde C, Verges R, Viñals J, Martin-Broto J. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46. doi: 10.1007/s00280-015-2809-5. Epub 2015 Nov 12.
  • Serrano C, Romagosa C, Hernández-Losa J, Simonetti S, Valverde C, Moliné T, Somoza R, Pérez M, Vélez R, Vergés R, Domínguez R, Carles J, Ramón Y Cajal S. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. Cancer. 2016 Jan 1;122(1):99-107. doi: 10.1002/cncr.29733. Epub 2015 Oct 19.
  • Barrera-Ochoa S, Gallardo-Calero I, López-Fernández A, Romagosa C, Vergés R, Aguirre-Canyadell M, Soldado F, Velez R. Effect of Previous Irradiation on Vascular Thrombosis of Microsurgical Anastomosis: A Preclinical Study in Rats. Plast Reconstr Surg Glob Open. 2016 Nov 23;4(11):e1073. DOI: 10.1097/GOX.0000000000001073
  • Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CM, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC). Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiother Oncol. 2016 Dec;121(3):431-439. doi: 10.1016/j.radonc.2016.06.017. Epub 2016 Jul 18.
  • Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J. Clin. Oncol. 2016 Apr; 34(12): 1300-8
  • Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb; 16(2): 208-20
  • Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesia R, Zhang A, Oliner KS, VanderWalde A. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb; 16(2): 221-32
  • Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014 Feb; 15(2): 184-90
  • Sclafani F, González D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Oates J, Chau I. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. Eur. J. Cancer 2014 May; 50(8): 1430-6
  • Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.Cancer Res. 2013 Jan; 73(1): 450-8
  • Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer 2013; 13: 84
  • Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J. Clin. Oncol. 2012 Sep; 30(26): 3187-93
  • Beltran M, Ramos M, Rovira JJ, Perez-Hoyos S, Sancho M, Puertas E, Benavente S, Ginjaume M, Giralt J. Dose variations in tumor volumes and organs at risk during IMRT for head-and-neck cancer. J Appl Clin Med Phys 2012; 13(6): 3723
  • Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massuti B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. Cancer Chemother. Pharmacol. 2011 Jan; 67(1): 75-82
  • Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan; 11(1): 21-8
  • Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J. Clin. Oncol. 2010 Jun; 28(18): 2996-3001
  • Peters LJ, Fitzgerald TJ, Giralt J, O’Sullivan B, Bernier J, Trotti A, Bourhis J, Yuen K, Fisher R, Rischin D. Radiotherapy Protocol Compliance And Quality In The Treatment Of Advanced Head and Neck Cancer – Results From Trog 02.02 J Clin Oncol 2010 jun; 28(18): 2996-3001
  • Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massuti B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.Int. J. Radiat. Oncol. Biol. Phys. 2009 Dec; 75(5): 1430-6
  • Varela E, Antolín M, Guarner F, Verges R, Giralt J, Malagelada JR. Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy. Aliment. Pharmacol. Ther. 2009 Jul; 30(2): 175-85
  • Benavente S, Verges R, Hermosilla E, Fumanal V, Casanova N, Garcia A, Ramón y Cajal S, Giralt J. Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2009 Dec; 75(5): 1316-22
  • Guarner L, Navalpotro B, Molero X, Giralt J, Malagelada JR. Management of painful chronic pancreatitis with single-dose radiotherapy. Am. J. Gastroenterol. 2009 Feb; 104(2): 349-55
  • Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006 Feb; 354(6): 567-78
  • Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espín E, Roselló J, Majo J, Benavente S, Armengol M, de Torres I. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005 Feb; 74(2): 101-8
  • Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004 May; 350(19): 1945-52

Projects

Funded Projects

  1. ENCANT – Nanoengineered particles for enhanced cancer radiotherapy. Reference: 101189443. Funded by: European Commission. 1/01/2025-30/08/2026. PI: Xavier Maldonado
  2. Catalan Clinical Audit network for Quality Improvement in RT (CAT-ClinART). Reference 101161063. Funded by European Commission. PI: Xavier Maldonado
  3. EURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitisation aspects – EURAMED rocc-n-roll. EU Horizon 2020 research and innovation programme. Grant agreement no: 899995.
  4. COGNITO: Evaluation of long-term cognitive effects in childhood cancer survivors. Reference: PR(AMI)389/2017. PI: Monica Ramos. EU project 899995 – EURAMED.

  Non-Funded Projects

  1. Adaptive radiation therapy based on PET functional imaging for H&N cancer patients.
  2. Breast irradiation, comparisons and analysis of dose distribution and reproducibility in supine versus prone position.
  3. Phase II clinical Essay extracranial stereotactic radiotherapy in the treatment of locally advanced prostate cancer.
  4. Instrumentation radiotherapy of the spine and paraspinal tumors and metastases.
  5. Extracranial stereotactic radiotherapy in pancreatic cancer, commissioning and validation of the technique.
  6. Techniques for reducing toxicity: radiotherapy treatment in the pediatric patients with brain tumors.
  7. Radiation treatment planning of gynecological tumors. Monitoring compliance in filling the urinary bladder.
  8. Total marrow irradiation program for bone marrow transplantation in patients with multiple myeloma; dosimetric studies.
  9. A feasibility trial evaluating anti-PD1 nivolumab consolidation after standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC.
  10. REQUITE project. Inclusion and monitoring of lung cancer patients.
  11. Adaptive radiotherapy in the treatment of patients with non-small cell lung neoplasia in stages IIA and IIB.(AG) 288/216.
  12. Extracranial stereotactic radiotherapy (SBRT) as a treatment for unresectable liver metastases.
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required